Parow Entheobiosciences
About
Parow Entheobiosciences (PEB) is a fully integrated, pre-clinical stage biotechnology company developing targeted entheogen therapeutics that ensure accessible treatment for patients with psychiatric diseases. PEB was founded in early 2021 to leverage Back of the Yards Algae Sciences’ (BYAS) expertise in industrial biotechnology and cell culture. PEB has a fully equipped facility including production, extraction and purification and a DEA licensed analytical laboratory.
Leadership
Karin Blakolmer MD MBA – CEO: Karin has over 20 years of oncology experience in early and late clinical development and global, US and Europe medical affairs in positions of increasing responsibility at Roche, Novartis, Amgen, Sanofi, Astellas and lastly as SVP of medical affairs at Taiho Oncology.
Leonard Lerer MD MBA – Founder, principal advisor and CFO: Founder of BYAS and PEB. 20+ years’ experience, including senior research and administrative positions, across the entire life sciences value chain. Employment across global pharmaceutical companies, investors, investment funds and international organizations including WHO and World Bank.
Prof. Bernard Lerer MD – Principal Scientific Advisor: Professor of Psychiatry at the Hebrew University of Jerusalem. Recognized as a major pioneer in neuropsychopharmacology, Bernard has served as director of the National Institute for Psychobiology in Israel. He is the Founder of Hadassah BrainLabs, a leading center in pre-clinical psychiatry and neurology pre-clinical research.
Rob Agterberg, BSc, BBA - COO, Netherlands Lead: Extensive experience as a senior consultant, notably at Cap Gemini E&Y focusing on life sciences. Specialty interests include artificial intelligence and innovative internet marketing technologies.
Partners
Our strategy is to work with the foremost researchers globally to identify and develop the best programmes. We have developed strong partnerships that enable it to accelerate identification and development of novel therapeutics.
Advisors
Prof. Harold Sackeim Ph.D. is Professor of Psychiatry and Radiology at The College of Physicians and Surgeons, Columbia University. He served as Chief of the Department of Biological Psychiatry at the New York State Psychiatric Institute for 25 years. He is also the Founding Editor of the journal, Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. He joined the faculty of Columbia University in 1977, where he remains today.
Prof. Jason Slot Ph.D. is Professor of Plant Pathology at The College of Agricultural and Environmental Science of Ohio State University. He is a recognized expert on fungal evolutionary genetics and has published key papers on psychedelic mushroom genomics and proteomics. He received his Ph.D. from the Biology Department of Clark University and did his post-doctoral research at Vanderbilt University.
Prof. Peter Lammers Ph.D. is research professor in the School of Sustainable Engineering and the Built Environment at Arizona State University. He is an expert on extremophile algae. His appointments include technical director of the Energy Research Laboratory at New Mexico State University, vice president for Biotechnology at Solix Biosystems molecular biology at New Mexico State University
He holds a Doctorate in environmental science- chemistry, followed by postdoc training at the University of Chicago
Harold Perlman CPA, MBA is an independent consultant. He was a Managing Director in Grant Thornton’s Transaction Advisory Services practice based in the Chicago office. Harold has more than 20 years of professional experience and specializes in due diligence. Over the last decade, Harold has provided merger & acquisition advisory services to financial and corporate clients on approximately 200 transactions. Harold has co-authored an article on working capital pitfalls in transactions, which was published in Buyouts Magazine.